BioCellgraft - BioCellgraft specializes in regenerative health therapies specifically designed to enhance soft and hard tissue regeneration within the oral cavity. Our flagship product, OraFyl, is a highly purified biological matrix derived from the chorionic portion of the human placenta (HPCTM - Human Placenta Connective Tissue Matrix). It consists of native collagen and elastin presented in their most purified molecular scaffold form.

From a biological standpoint, the antibacterial and anti-fibrotic properties of chorion-derived products provided reassurance that the grafted site remained protected from bacterial colonization. This translated into a cleaner site at implant placement, where I observed dense, well-integrated bone with no graft particle migration—a common issue with other materials. Additionally, the soft tissue volume was ideal, allowing for excellent emergence profile customization and improved esthetic outcomes.  In follow-ups, patients demonstrated rapid healing and full restoration of ridge morphology, further confirming OraFyl®’s role in promoting predictable, high-quality outcomes. This material has become a key component in my approach to ridge preservation, enhancing both efficiency and clinical success.  Dr B. Husseini 

“We are excited to partner with Celularity to bring these exceptional regenerative therapies to the dental market in the United States. The existing data supports the tremendous opportunity we have to assist oral healthcare practitioners with extremely difficult indications which often involve painful procedures that are long and require many visits"

"Oral health is fundamental to overall health. This opportunity to manufacture placental-derived biomaterials for BioCellgraft will bring our exceptional, proven biomaterial technology to the treatment of oral healthcare concerns and fill the treatment gap for patients that suffer from soft tissue and hard tissue conditions”